A5084132378- Psoriasis: Treatment and Pathogenesis
- SARS-CoV-2 and COVID-19 Research
- Melanoma and MAPK Pathways
- Monoclonal and Polyclonal Antibodies Research
- Inflammasome and immune disorders
- Cutaneous Melanoma Detection and Management
- Systemic Lupus Erythematosus Research
- Atherosclerosis and Cardiovascular Diseases
- HER2/EGFR in Cancer Research
- COVID-19 Clinical Research Studies
- Peripheral Neuropathies and Disorders
- Cytokine Signaling Pathways and Interactions
- Biosimilars and Bioanalytical Methods
- Lymphatic System and Diseases
- IL-33, ST2, and ILC Pathways
- Heparin-Induced Thrombocytopenia and Thrombosis
- Spondyloarthritis Studies and Treatments
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
Semmelweis University
2021-2024
Abstract Immune‐mediated inflammatory disease (IMID) patients including psoriasis, arthritides and bowel diseases have a higher risk of developing cardiovascular (CV) compared to the general population. The increased CV may be promoted by tumour necrosis factor (TNF)‐α‐mediated immunological processes, which are present both in pathomechanism IMIDs atherosclerosis. Our objective was comprehensively investigate effect TNF inhibitors (TNFi) on with conventional therapies IMIDs. systematic...
Background: Psoriasis is frequently accompanied by cardiovascular diseases based on the shared immunopathogenic pathway. Authors determined effect of interleukin (IL)-17 inhibitor therapy arterial intima-media thickness (IMT) among severe psoriatic patients. Methods: Thirty-one patients were enrolled. Twenty received secukinumab and 11 ixekizumab. Before treatment initiation after 6 months, carotid-brachial-femoral IMT, Area Severity Index (PASI), Dermatology Life Quality (DLQI) EuroQol...
It is unclear whether biological antipsoriatic therapies affect seroconversion after messenger ribonucleic acid (mRNA)-based antisevere acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) vaccinations. To assess antibody formation and the incidence of side effects anti-SARS-CoV-2 mRNA vaccinations in psoriatic patients receiving different biologicals compared to healthy controls. 102 moderate-to-severe (56.2 [±13.5] years) 55 age-matched (56.4 ± 13.6 volunteers were included our...